Cartalax 20mg

Cartalax 20 mg

CAS Number: 827306-88-7
Synonyms: Cartalax Peptide, AEDG Tetrapeptide, Cytoprotective Tetrapeptide
Quantity: 20 mg (lyophilised)

Key Features

• Purity: ≥ 98% (HPLC-verified)
• Endotoxin: ≤ 5 EU/mg
• Form: Freeze-dried (lyophilised) powder
• Documentation: COA supplied with every lot

Peptide Information

• Sequence: Ala-Glu-Asp-Gly (AEDG)
• Length: 4 amino acids
• Molecular Formula: C₁₄H₂₀N₄O₉
• Molecular Weight: 388.33 g/mol
• Classification: Synthetic regulatory peptide for research workflows, including gene-expression studies, cellular regulation assays, peptide characterisation, and structural analysis applications.

Peptide Origin & Derivation

Cartalax belongs to the short regulatory peptide family originally isolated from cartilage tissue extracts. Specifically, researchers classify it within the same group of tetrapeptides associated with cartilage-derived peptide complexes. Scientists derived Cartalax from naturally occurring peptide fractions identified in animal cartilage tissue. As a result, the peptide represents the minimal active fragment linked to the regulatory characteristics observed in those extracts.

In modern laboratory environments, researchers produce Cartalax synthetically to maintain:

• Sequence fidelity
• High purity
• Batch-to-batch reproducibility

Additionally, the synthetic AEDG tetrapeptide contains a structurally conserved motif found in several naturally occurring cytoprotective peptide families.

Research Applications & Laboratory Relevance

Cartalax (AEDG tetrapeptide) continues to attract attention in peptide research because of its compact structure, stability profile, and compatibility with controlled laboratory workflows. Furthermore, researchers commonly investigate this short-chain regulatory peptide in studies involving cellular signalling pathways, extracellular matrix interactions, cartilage-associated molecular processes, and peptide-mediated gene expression mechanisms.

In addition, scientists explore the relevance of AEDG motifs within broader peptide-regulation studies due to their conserved amino acid arrangement and reproducible synthetic structure. Consequently, many laboratories value Cartalax for analytical consistency, defined composition, and compatibility with molecular biology workflows.

The lyophilised format also supports extended storage stability while allowing accurate handling and preparation during controlled research procedures. Moreover, the defined tetrapeptide structure makes Cartalax suitable for peptide characterisation studies, structural analysis workflows, and experimental systems requiring high-purity synthetic peptide materials.

Storage & Stability

• Long-term: –20 °C, dry and protected from light
• Short-term: Stable at 2–8 °C
• Note: Avoid repeated freeze-thaw cycles

Intended Use

For laboratory research only. This product is not for human or veterinary use. Furthermore, regulatory authorities have not approved Cartalax for diagnostic, therapeutic, or medical applications. Therefore, laboratories should handle this material using appropriate research safety practices.

Why Choose Cartalax 20 mg?

• High-purity synthetic peptide suitable for sensitive molecular and cellular systems
• Full batch traceability
• COA included with every lot
• Lyophilised for extended stability and ease of handling

Search-Optimised Keywords

Cartalax, Cartalax peptide, AEDG peptide, Cartalax CAS 827306-88-7, Cartalax 20 mg, Cartalax research peptide, synthetic AEDG, regulatory peptide AEDG, Cartalax laboratory reagent, lyophilised Cartalax peptide, synthetic tetrapeptide research compound, cartilage-derived regulatory peptide.